• Our Solution
    • Physicians
    • Patients
  • About Artrya
    • Who we are
    • Leadership Team
    • Board of Directors
    • Careers
  • Investor Relations
    • Overview
    • ASX Announcements
    • Corporate Governance
    • Company Research
  • Contact Us
Request a demonstration

Rescheduled Investor Call

Quarterly Activity Report and Appendix 4C-June 2023

Change of Director’s Interest Notice – John Barrington

Notification of cessation of securities – AYA

Secondary Trading Notice

Company Presentation – MST Digital Health Forum

AYA Conducts Successful Q-Submission Meeting with FDA

Application for quotation of securities – AYA

Change of Director’s Interest Notice – K Hill

Artrya Lodges Key Submission in FDA Process

Previous 1 2 3 4 5 Next

Precise diagnosis. Personalized treatment.
Preventative care.

Choose Artrya as your trusted clinical partner.

Contact us today
Coronary artery disease.
We see you.

Sign up to our newsletter

Request a Demo
Contact Us

About Artrya
Investor Relations

Location
1257 Hay Street, West Perth, 6005
Follow us
X
LinkedIn

Salix Coronary Anatomy is listed on the Australian Register of Therapeutic Goods, ID 347719.  Salix Coronary Anatomy USA product (K243038) is cleared in the USA. 
For the availability of Salix in the EU, UK, US or other jurisdictions, please contact us.

© 2025, Artrya. All rights reserved. Privacy Policy Terms and Conditions Indications for Use